Preferences help
enabled [disable] Abstract
Number of results
2014 | 41 | 1 | 93-105
Article title

Udział zaburzeń szlaku FGF/FGFR w transformacji nowotworowej piersi, jajnika oraz błony śluzowej trzonu macicy

Title variants
The role of FGF/FGFR signaling pathway disorders in breast, ovarian and endometrial cancerogenesis
Languages of publication
Czynniki wzrostu fibroblastów (FGF) oraz ich receptory (FGFR) stanowią liczną rodzinę białek zaangażowanych w regulację wielu procesów kluczowych dla prawidłowego funkcjonowania komórek. Na przestrzeni ostatnich lat wykazano, że zaburzenia szlaku FGF/FGFR odgrywać mogą istotną rolę w transformacji nowotworowej wielu narządów, w tym piersi, jajnika i endometrium. Nieprawidłowa ekspresja genów kodujących FGF i ich receptory, a także ich mutacje skutkować mogą zaburzeniami procesów wzrostu i apoptozy. Zaburzenia sygnalizacji szlaku FGF/FGFR mogą również leżeć u podstaw nabywania przez komórki nowotworowe oporności na terapię hormonalną.
Fibroblast growth factors (FGFs) and their receptors (FGFRs) are the members of a large protein family involved in the regulation of many cellular processes which are essential for proper functioning of cells. It was found that the disregulation of FGF/FGFR signaling pathway can lead to the cancerogenesis of many tissues including the breast, the ovary and the endometrium. The alteration in FGF and FGFR gene expression and their mutation may induce growth and survival signals and suppress apoptosis. The Disregulation of FGF/FGFR signaling pathway can also promote endocrine therapy resistance.
Physical description
  • Katedra Cytobiochemii, Wydział Biologii i Ochrony Środowiska, Uniwersytet Łódzki
  • Katedra Cytobiochemii, Wydział Biologii i Ochrony Środowiska, Uniwersytet Łódzki
  • Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012; 18: 1855-1862.
  • Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001; 2(3): REVIEWS3005.
  • Fearon AE, Gould CR, Grose RP. FGFR signaling in women's cancers. Int J Biochem Cell Biol. 2013; 45: 2832-2842.
  • Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009; 8: 235-253.
  • Beenken A, Mohammadi M. The structural biology of the FGF19 subfamily. Adv Exp Med Biol. 2012; 728: 1-24.
  • Belov AA, Mohammadi M. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect Biol. 2013; 1;5. pii: a015958
  • Itoh N, Ornitz, DM. Evolution of the Fgf and Fgfr gene families. Trends Genet. 2004; 20: 563-569.
  • Tenhagen M, van Diest PJ, Ivanova IA, van der Wall E, van der Groep P. Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets. EndocrRelat Cancer. 2012; 19: R115-129.
  • Haugsten EM, Wiedlocha A, Olsnes S, Wesche J. Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res. 2010; 8:1439-1452.
  • Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J. 2011; 437: 199-213.
  • Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005; 16: 139-149.
  • Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem. 2011; 149:121-130
  • Ahmad I, Iwata T, Leung HY. Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta. 2012; 1823: 850-860.
  • Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10: 116-129.
  • Wu X, Weiszmann J, Ge H, Baribault H, Stevens J, Hawkins i wsp. A unique FGF23 with the ability to activate FGFR signaling through both αKlotho and βKlotho. J Mol Biol. 2012; 418: 82-89.
  • Medici D, Razzaque MS, Deluca S, Rector TL, Hou B, Kang K i wsp. FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis. J Cell Biol. 2008; 182: 459-465.
  • Nilsson EM, Brokken LJ, Harkonen PL. Fibroblast growth factor 8 increases breast cancer cell growth by promoting cell cycle progression and by protecting against cell death. Exp. Cell Res. 2010; 316: 800-812.
  • Elbauomy Elsheikh S, Green AR, Lambros MB, Turner NC, Grainge MJ, PoweD i wsp. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res. 2007; 9: R23.
  • Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA i wsp. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010 ;70: 2085-2094.
  • Tomlinson DC, Knowles MA, Speirs V. Mechanisms of FGFR3 actions in endocrine resistant breast cancer. Int J Cancer. 2012; 130: 2857-2866.
  • Roidl A, Berger HJ, Kumar S, Bange J, Knyazev P, Ullrich A. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin. Cancer Res. 2009; 15: 2058-2066.
  • Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R i wsp. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010; 29: 2013-2023.
  • Shi HL, Yang T, Deffar K, Dong CG, Liu JY, Fu CL i wsp. A novel single-chain variable fragment antibody against FGF-1 inhibits the growth of breast carcinoma cells by blocking the intracrine pathway of FGF-1. IUBMB Life. 2011; 63:129-137.
  • Shi H, Fu C, Wang W, Li Y, Du S, Cao R i wsp. The FGF-1-specific single-chain antibody scFv1C9 effectively inhibits breast cancer tumour growth and metastasis. J Cell Mol Med. 2014; 18: 2061-2070.
  • Rosen A, Sevelda P, Klein M, Dobianer K, Hruza C, Czerwenka K i wsp. First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer. Br J Cancer. 1993; 67: 1122-1125.
  • Cole C, Lau S, Backen A, Clamp A, Rushton G, Dive C i wsp. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer BiolTher. 2010; 10(5): 495-504.
  • Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A i wsp. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced stage serous ovarian adenocarcinomas. J Clin Oncol 2007; 25: 2281-2287.
  • Byron SA, Gartside MG, Wellens CL, Goodfellow PJ, Birrer MJ, Campbell IG, Pollock PM. FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecol Oncol. 2010; 117(1): 125-129.
  • Zecchini S, Bombardelli L, Decio A, Bianchi M, Mazzarol G, Sanguineti F i wsp. The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. Embo Mol Med. 2011; 3: 480-494.
  • Pollock, PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H i wsp. Frequent activating FGFR2 mutations in endometrial carcinomas paralel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007; 26: 7158-7162.
  • Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA i wsp. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res. 2008; 68(17): 6902-6907.
  • Gatius S, Velasco A, Azueta A, Santacana M, Pallares J, Valls J i wsp. FGFR2 alterations in endometrial carcinoma. Mod Pathol. 2011; 24: 1500-1510.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.